Jeonbuk National University Hospital | Clinical Pharmacology Center
Status and phase
Conditions
Treatments
About
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Full description
This is a randomized phase 2 (open-label) / 3 (double-blind), international, multi-center study of patients with metastatic HER2-overexpressing gastric/GEJ adenocarcinoma that has progressed on or after prior HER2-directed therapy and fluoropyrimidine- or platinum-containing chemotherapy and are suitable for chemotherapy (2nd-line or 3rd-line). Approximately 450 adult patients are expected to be enrolled in the study across both phases.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
450 participants in 4 patient groups
Loading...
Central trial contact
Philip Fanning, PhD; Sophia Randolph, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal